Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Liposomal encapsulation of doxorubicin is designed to increase safety and tolerability by decreasing cardiac and gastrointestinal toxicity through decreased exposure of these tissues to doxorubicin, while effectively delivering drug to the tumor. We conducted an open-label phase I study to determine the pharmacokinetic profile of a single dose of liposome-encapsulated doxorubicin (Myocet) in patients with various solid tumors. Safety and tolerability were monitored.

Experimental design

Patients received a single intravenous infusion of Myocet 75 mg/m2. Plasma samples were analyzed for concentration of liposome-encapsulated doxorubicin, total doxorubicin, and doxorubicinol.

Results

A total of 18 patients aged 20–73 years (median 60 years) participated; 17 were evaluable for pharmacokinetic analysis. The most common primary tumor was soft tissue sarcoma (22%). Total body clearance for total doxorubicin was 5.6 l/h/m2 while the volume (Vss) was 82 l/m2. The terminal half-life was 52.6 h. Based on the AUC and Cmax values for total doxorubicin and encapsulated doxorubicin, an estimated 85% of circulating doxorubicin was encapsulated. Doxorubicinol was detected in all patients; the mean AUC was 2.03±1.10 μmol/l/h. The mean 48-h urinary excretion of doxorubicin was 6.44% of the dose. The most common adverse events were nausea (94%), fatigue (78%) and vomiting (67%). Cardiotoxicity (measured as ten-point fall in LVEF to <50%) was observed in one patient. Pharmacokinetic values did not correlate with hematological, laboratory or demographic variables.

Conclusions

The pharmacokinetic profile of Myocet suggests that the liposomal formulation results in a longer half-life with less free drug available for tissue distribution than conventional doxorubicin, consistent with the enhanced therapeutic index observed in clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905

    Article  CAS  PubMed  Google Scholar 

  2. Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr, Tkaczuk KH, Boxenbaum H, Welles L, Chow S-C, Bhamra R, Chasikin P (2003) Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 14:239–246

    Article  CAS  PubMed  Google Scholar 

  3. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444–1454

    CAS  PubMed  Google Scholar 

  4. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25–36

    Article  CAS  PubMed  Google Scholar 

  5. Chabner BA, Allegra CJ, Curt GA, Calabresi P (1996) Antineoplastic agents. In: Hardman JG, Limbird LE (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York, pp 1264–1266

  6. Takanashi S, Bachur N (1976) Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos 4:79–87

    CAS  PubMed  Google Scholar 

  7. Mross K, Maessen P, van der Vijgh WJF, Gall H, Boven E, Pinedo HM (1988) Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517–526

    CAS  PubMed  Google Scholar 

  8. Speth PAJ, Van Hoesel QGCM, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15–31

    CAS  PubMed  Google Scholar 

  9. Loo TL, Freireich EJ (1995) Cancer chemotherapeutic drugs. In: PL Munson (ed) Principles of pharmacology: basic concepts and clinical application. Chapman & Hall, New York, pp 1475–1516

  10. Robert J (1998) Anthracyclines. In: Grochow LB, Ames MM (eds) A clinician’s guide to chemotherapy: pharmacokinetics and pharmacodynamics. William and Wilkins, Philadelphia

  11. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker

  12. Chan KKH, Gibaldi M (1982) Estimation of statistical moments and steady-state volume of distribution for a drug given by intravenous infusion. J Pharmacokinet Biopharm 10:551–558

    CAS  PubMed  Google Scholar 

  13. Robert J, Gianni L (1993) Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17:219–252

    CAS  PubMed  Google Scholar 

  14. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 21:221–228

    CAS  PubMed  Google Scholar 

  15. Jacquet J-M, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, Rossi JF (1990) Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 27:219–225

    CAS  PubMed  Google Scholar 

  16. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53:555–561

    CAS  PubMed  Google Scholar 

  17. Amantea MA, Forrest A, Northfeldt DW, Mamelok R (1997) Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Clin Pharmacol Ther 61:301–311

    CAS  PubMed  Google Scholar 

  18. Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I, et al (2002) EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol 13:910–918

    Article  CAS  PubMed  Google Scholar 

  19. Keller AM, Mennel RG, Nabholtz JM, Georgoulias V, Emanuel DJ, Tendler CL (2001) Phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxane-containing chemotherapy regimen. Proceedings of the Annual Meeting of the American Society of Clinical Oncology, abstract 115

  20. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037–1047

    Article  CAS  PubMed  Google Scholar 

  21. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136:1475–1480

    Google Scholar 

  22. Hong RL, Tseng YL (2001) Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 91:1826–1833

    Article  CAS  PubMed  Google Scholar 

  23. Mross K (1993) Klinische und pharmakologische Untersuchungen zur Pharmakokinetik, Metabolisierung, Pharmakodynamik und Toxizität von Anthrazyklinen W. Zuckschwerdt Verlag München, Aktuelle Onkologie 76

  24. Massing U, Fuxius S (2000) Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat 3:171–177

    Article  CAS  PubMed  Google Scholar 

  25. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang F, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987–992

    CAS  PubMed  Google Scholar 

  26. Mross K, Gierlich T, Häring B, März W, Unger C (2002) Clinical and pharmacokinetics study with liposomal doxorubicin (DL-1) in patients with advanced metastatic cancer—results from a phase-I study. Int J Clin Pharmacol Ther 40:387–388

    CAS  Google Scholar 

Download references

Acknowledgement

This study was sponsored by The Liposome Company, Princeton, NJ, USA (now Medeus Pharmaceuticals, Inc.).

Author information

Authors and Affiliations

  1. Tumor Biology Center, Albert-Ludwigs University Freiburg, 79106, Freiburg im Breisgau, Germany

    Klaus Mross, Bernward Niemann, Ulrich Massing, Joachim Drevs & Clemens Unger

  2. The Liposome Company, Princeton, NJ, USA

    Rupinder Bhamra & Christine E. Swenson

Authors
  1. Klaus Mross
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernward Niemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrich Massing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joachim Drevs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clemens Unger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rupinder Bhamra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christine E. Swenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Mross.

Additional information

The Liposome Company is now Medeus Pharmaceuticals, Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mross, K., Niemann, B., Massing, U. et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol 54, 514–524 (2004). https://doi.org/10.1007/s00280-004-0825-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0825-y

Keywords

Search

Navigation